# LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

> **NCT03377426** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Complicated Urinary Tract Infections

## Interventions

- **DRUG:** LYS228
- **DRUG:** Standard of care therapy

## Key facts

- **NCT ID:** NCT03377426
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-19
- **Primary completion:** 2019-10-28
- **Final completion:** 2019-10-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was terminated due to an out-licensing agreement after the new sponsor did not wish to continue the trial
- **Last updated:** 2018-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377426, "LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03377426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*